{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T16:40:41Z","timestamp":1787244041190,"version":"build-2736575974"},"reference-count":131,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2019,5,1]],"date-time":"2019-05-01T00:00:00Z","timestamp":1556668800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,5,1]],"date-time":"2019-05-01T00:00:00Z","timestamp":1556668800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"Vectura"},{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002590","name":"American Lung Association","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002590","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006093","name":"PCORI)","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006093","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Boeringer Ingelheim"},{"DOI":"10.13039\/100007560","name":"Chiesi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007560","id-type":"DOI","asserted-by":"publisher"}]},{"name":"GSK"},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004339","name":"Sanofi-Aventis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Ception"},{"DOI":"10.13039\/100004388","name":"Cephalon","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004388","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Teva"},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"name":"GSK"},{"DOI":"10.13039\/100004339","name":"Sanofi-Aventis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Vectura"},{"name":"KaloBios"},{"DOI":"10.13039\/501100004628","name":"MedImmune","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004628","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Vectura"},{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002590","name":"American Lung Association","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002590","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006093","name":"PCORI","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006093","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Boeringer Ingelheim"},{"DOI":"10.13039\/100007560","name":"Chiesi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007560","id-type":"DOI","asserted-by":"publisher"}]},{"name":"GSK"},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004339","name":"Sanofi-Aventis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Ception"},{"DOI":"10.13039\/100004388","name":"Cephalon","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004388","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Teva"},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"name":"GSK"},{"DOI":"10.13039\/100004339","name":"Sanofi-Aventis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Vectura"},{"name":"KaloBios"},{"DOI":"10.13039\/501100004628","name":"MedImmune","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004628","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaci-inpractice.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Allergy and Clinical Immunology: In Practice"],"published-print":{"date-parts":[[2019,5]]},"DOI":"10.1016\/j.jaip.2019.03.008","type":"journal-article","created":{"date-parts":[[2019,5,8]],"date-time":"2019-05-08T21:47:53Z","timestamp":1557352073000},"page":"1379-1392","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":59,"title":["Biologics for Severe Asthma: Treatment-Specific Effects Are Important in Choosing a Specific Agent"],"prefix":"10.1016","volume":"7","author":[{"given":"James G.","family":"Krings","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary Clare","family":"McGregor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonard B.","family":"Bacharier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"Castro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaip.2019.03.008_bib1","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1186\/1471-2458-12-204","article-title":"Global asthma prevalence in adults: findings from the cross-sectional world health survey","volume":"12","author":"To","year":"2012","journal-title":"BMC Public Health"},{"key":"10.1016\/j.jaip.2019.03.008_bib2","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1111\/j.1398-9995.2004.00526.x","article-title":"The global burden of asthma: executive summary of the GINA Dissemination Committee report","volume":"59","author":"Masoli","year":"2004","journal-title":"Allergy"},{"key":"10.1016\/j.jaip.2019.03.008_bib3","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/cc1451","article-title":"Clinical review: severe asthma","volume":"6","author":"Papiris","year":"2002","journal-title":"Crit Care"},{"key":"10.1016\/j.jaip.2019.03.008_bib4","doi-asserted-by":"crossref","first-page":"124","DOI":"10.3109\/02770900903518835","article-title":"Factors associated with the control of severe asthma","volume":"47","author":"Hermosa","year":"2010","journal-title":"J\u00a0Asthma"},{"key":"10.1016\/j.jaip.2019.03.008_bib5","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1016\/j.jaip.2014.02.011","article-title":"Impact of asthma exacerbations and asthma triggers on asthma-related quality of life in patients with severe or difficult-to-treat asthma","volume":"2","author":"Luskin","year":"2014","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2019.03.008_bib6","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/s40413-017-0159-y","article-title":"Severe asthma and quality of life","volume":"10","author":"Hossny","year":"2017","journal-title":"World Allergy Organ J"},{"key":"10.1016\/j.jaip.2019.03.008_bib7","doi-asserted-by":"crossref","first-page":"142","DOI":"10.7326\/0003-4819-127-2-199707150-00009","article-title":"Observations on asthma mortality","volume":"127","author":"McFadden","year":"1997","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jaip.2019.03.008_bib8","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1183\/13993003.00779-2015","article-title":"Clinical and inflammatory characteristics of the European U-BIOPRED adult severe asthma cohort","volume":"46","author":"Shaw","year":"2015","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jaip.2019.03.008_bib9","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.jaci.2006.11.639","article-title":"Characterization of the severe asthma phenotype by the National Heart, Lung, and Blood Institute\u2019s Severe Asthma Research Program","volume":"119","author":"Moore","year":"2007","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2019.03.008_bib10","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.jaci.2017.04.009","article-title":"Oral corticosteroid exposure and adverse effects in asthmatic patients","volume":"141","author":"Sullivan","year":"2018","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2019.03.008_bib12","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1016\/j.jaip.2017.04.027","article-title":"Management of severe asthma before referral to the severe asthma specialist","volume":"5","author":"Carr","year":"2017","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2019.03.008_bib13","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1016\/S2213-2600(16)30018-2","article-title":"Bronchial thermoplasty and biological therapy as targeted treatments for severe uncontrolled asthma","volume":"4","author":"Trivedi","year":"2016","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.jaip.2019.03.008_bib14","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.jaip.2014.09.014","article-title":"Biologics in asthma--the next step toward personalized treatment","volume":"3","author":"Darveaux","year":"2015","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2019.03.008_bib15","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.anai.2016.05.016","article-title":"Characterization of asthma endotypes: implications for therapy","volume":"117","author":"Stokes","year":"2016","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jaip.2019.03.008_bib16","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1111\/cea.12880","article-title":"Revisiting type 2-high and type 2-low airway inflammation in asthma: current knowledge and therapeutic implications","volume":"47","author":"Robinson","year":"2017","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/j.jaip.2019.03.008_bib17","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1016\/j.jaip.2017.04.038","article-title":"Biologic therapy and novel molecular targets of severe asthma","volume":"5","author":"Pepper","year":"2017","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2019.03.008_bib18","first-page":"CD010834","article-title":"Mepolizumab versus placebo for asthma","author":"Powell","year":"2015","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.jaip.2019.03.008_bib19","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1056\/NEJMoa1403290","article-title":"Mepolizumab treatment in patients with severe eosinophilic asthma","volume":"371","author":"Ortega","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jaip.2019.03.008_bib20","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1056\/NEJMoa1403291","article-title":"Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma","volume":"371","author":"Bel","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jaip.2019.03.008_bib21","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1164\/rccm.201103-0396OC","article-title":"Reslizumab for poorly controlled, eosinophilic asthma: a randomized, placebo-controlled study","volume":"184","author":"Castro","year":"2011","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jaip.2019.03.008_bib22","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/S2213-2600(15)00042-9","article-title":"Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials","volume":"3","author":"Castro","year":"2015","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.jaip.2019.03.008_bib23","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1016\/j.chest.2016.03.032","article-title":"Reslizumab for inadequately controlled asthma with elevated blood eosinophil levels: a randomized phase 3 study","volume":"150","author":"Bjermer","year":"2016","journal-title":"Chest"},{"key":"10.1016\/j.jaip.2019.03.008_bib24","doi-asserted-by":"crossref","first-page":"2128","DOI":"10.1016\/S0140-6736(16)31322-8","article-title":"Benralizumab, an anti-interleukin-5 receptor alpha monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial","volume":"388","author":"FitzGerald","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.jaip.2019.03.008_bib25","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.1016\/S0140-6736(16)31324-1","article-title":"Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting beta2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial","volume":"388","author":"Bleecker","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.jaip.2019.03.008_bib26","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1016\/j.chest.2016.03.018","article-title":"Phase 3 study of reslizumab in patients with poorly controlled asthma: effects across a broad range of eosinophil counts","volume":"150","author":"Corren","year":"2016","journal-title":"Chest"},{"key":"10.1016\/j.jaip.2019.03.008_bib27","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1056\/NEJMoa1804092","article-title":"Dupilumab efficacy and safety in moderate-to-severe uncontrolled asthma","volume":"378","author":"Castro","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jaip.2019.03.008_bib28","doi-asserted-by":"crossref","first-page":"2475","DOI":"10.1056\/NEJMoa1804093","article-title":"Efficacy and safety of dupilumab in glucocorticoid-dependent severe asthma","volume":"378","author":"Rabe","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jaip.2019.03.008_bib29","first-page":"CD003559","article-title":"Omalizumab for asthma in adults and children","author":"Normansell","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.jaip.2019.03.008_bib30","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1183\/09031936.01.00092101","article-title":"The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics","volume":"18","author":"Soler","year":"2001","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jaip.2019.03.008_bib31","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1111\/j.1365-2222.2004.1916.x","article-title":"Efficacy and safety of a recombinant anti-immunoglobulin E antibody (omalizumab) in severe allergic asthma","volume":"34","author":"Holgate","year":"2004","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/j.jaip.2019.03.008_bib32","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1097\/MCP.0000000000000434","article-title":"Precision medicine in asthma: linking phenotypes to targeted treatments","volume":"24","author":"Chung","year":"2018","journal-title":"Curr Opin Pulm Med"},{"key":"10.1016\/j.jaip.2019.03.008_bib33","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1097\/ACI.0000000000000416","article-title":"Asthma: personalized and precision medicine","volume":"18","author":"Canonica","year":"2018","journal-title":"Curr Opin Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2019.03.008_bib34","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1016\/S0140-6736(06)69290-8","article-title":"Asthma: defining of the persistent adult phenotypes","volume":"368","author":"Wenzel","year":"2006","journal-title":"Lancet"},{"key":"10.1016\/j.jaip.2019.03.008_bib35","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1016\/j.pupt.2013.07.003","article-title":"Complex phenotypes in asthma: current definitions","volume":"26","author":"Wenzel","year":"2013","journal-title":"Pulm Pharmacol Ther"},{"key":"10.1016\/j.jaip.2019.03.008_bib36","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1164\/rccm.200906-0896OC","article-title":"Identification of asthma phenotypes using cluster analysis in the Severe Asthma Research Program","volume":"181","author":"Moore","year":"2010","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jaip.2019.03.008_bib37","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1111\/all.12136","article-title":"Three phenotypes of adult-onset asthma","volume":"68","author":"Amelink","year":"2013","journal-title":"Allergy"},{"key":"10.1016\/j.jaip.2019.03.008_bib38","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1016\/j.jaci.2013.10.006","article-title":"Phenotypes determined by cluster analysis in severe or difficult-to-treat asthma","volume":"133","author":"Schatz","year":"2014","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2019.03.008_bib39","doi-asserted-by":"crossref","first-page":"e102987","DOI":"10.1371\/journal.pone.0102987","article-title":"Statistical cluster analysis of the British Thoracic Society Severe refractory Asthma Registry: clinical outcomes and phenotype stability","volume":"9","author":"Newby","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.jaip.2019.03.008_bib40","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1164\/rccm.200711-1754OC","article-title":"Cluster analysis and clinical asthma phenotypes","volume":"178","author":"Haldar","year":"2008","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jaip.2019.03.008_bib41","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.jaci.2010.11.037","article-title":"Asthma endotypes: a new approach to classification of disease entities within the asthma syndrome","volume":"127","author":"Lotvall","year":"2011","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2019.03.008_bib42","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1111\/j.1365-2222.2011.03929.x","article-title":"Severe asthma: from characteristics to phenotypes to endotypes","volume":"42","author":"Wenzel","year":"2012","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/j.jaip.2019.03.008_bib43","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1038\/nrd3792","article-title":"The potential of biologics for the treatment of asthma","volume":"11","author":"Pelaia","year":"2012","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.jaip.2019.03.008_bib44","doi-asserted-by":"crossref","first-page":"3","DOI":"10.4168\/aair.2017.9.1.3","article-title":"Development of new therapies for severe asthma","volume":"9","author":"Fajt","year":"2017","journal-title":"Allergy Asthma Immunol Res"},{"key":"10.1016\/j.jaip.2019.03.008_bib45","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1038\/nri3786","article-title":"Type 2 inflammation in asthma\u2013present in most, absent in many","volume":"15","author":"Fahy","year":"2015","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.jaip.2019.03.008_bib46","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/j.cell.2010.03.004","article-title":"Asthma and allergic inflammation","volume":"140","author":"Locksley","year":"2010","journal-title":"Cell"},{"key":"10.1016\/j.jaip.2019.03.008_bib47","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1186\/rr39","article-title":"Th2 cytokines and asthma: an introduction","volume":"2","author":"Barnes","year":"2001","journal-title":"Respir Res"},{"key":"10.1016\/j.jaip.2019.03.008_bib48","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1159\/000024043","article-title":"IgE inhibition as a therapy for allergic disease","volume":"118","author":"Jardieu","year":"1999","journal-title":"Int Arch Allergy Immunol"},{"key":"10.1016\/j.jaip.2019.03.008_bib49","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.1056\/NEJM199912233412603","article-title":"Treatment of allergic asthma with monoclonal anti-IgE antibody. rhuMAb-E25 Study Group","volume":"341","author":"Milgrom","year":"1999","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jaip.2019.03.008_bib50","doi-asserted-by":"crossref","first-page":"2689","DOI":"10.1056\/NEJMct055184","article-title":"Omalizumab for asthma","volume":"354","author":"Strunk","year":"2006","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jaip.2019.03.008_bib51","doi-asserted-by":"crossref","first-page":"26368","DOI":"10.1016\/S0021-9258(18)47203-1","article-title":"The binding site on human immunoglobulin E for its high affinity receptor","volume":"269","author":"Presta","year":"1994","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.jaip.2019.03.008_bib52","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1159\/000237058","article-title":"Anti-IgE monoclonal antibodies that inhibit allergen-specific histamine release","volume":"107","author":"Shields","year":"1995","journal-title":"Int Arch Allergy Immunol"},{"key":"10.1016\/j.jaip.2019.03.008_bib53","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/j.jaip.2014.03.010","article-title":"Omalizumab in asthma: an update on recent developments","volume":"2","author":"Humbert","year":"2014","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2019.03.008_bib54","doi-asserted-by":"crossref","first-page":"573","DOI":"10.7326\/0003-4819-154-9-201105030-00002","article-title":"Omalizumab in severe allergic asthma inadequately controlled with standard therapy: a randomized trial","volume":"154","author":"Hanania","year":"2011","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jaip.2019.03.008_bib55","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1111\/j.1398-9995.2004.00772.x","article-title":"Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE","volume":"60","author":"Humbert","year":"2005","journal-title":"Allergy"},{"key":"10.1016\/j.jaip.2019.03.008_bib56","doi-asserted-by":"crossref","first-page":"e011857","DOI":"10.1136\/bmjopen-2016-011857","article-title":"Impact of omalizumab on treatment of severe allergic asthma in UK clinical practice: a UK multicentre observational study (the APEX II study)","volume":"6","author":"Niven","year":"2016","journal-title":"BMJ Open"},{"key":"10.1016\/j.jaip.2019.03.008_bib57","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1067\/mai.2001.117880","article-title":"Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma","volume":"108","author":"Busse","year":"2001","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2019.03.008_bib58","doi-asserted-by":"crossref","first-page":"E36","DOI":"10.1542\/peds.108.2.e36","article-title":"Treatment of childhood asthma with anti-immunoglobulin E antibody (omalizumab)","volume":"108","author":"Milgrom","year":"2001","journal-title":"Pediatrics"},{"key":"10.1016\/j.jaip.2019.03.008_bib59","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1111\/j.1440-1843.2009.01633.x","article-title":"Efficacy and safety of omalizumab in an Asian population with moderate-to-severe persistent asthma","volume":"14","author":"Ohta","year":"2009","journal-title":"Respirology"},{"key":"10.1016\/j.jaip.2019.03.008_bib60","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1056\/NEJMoa1009705","article-title":"Randomized trial of omalizumab (anti-IgE) for asthma in inner-city children","volume":"364","author":"Busse","year":"2011","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jaip.2019.03.008_bib61","doi-asserted-by":"crossref","first-page":"144","DOI":"10.3109\/02770903.2011.648296","article-title":"A\u00a026-week, randomized, double-blind, placebo-controlled, multicenter study to evaluate the effect of omalizumab on asthma control in patients with persistent allergic asthma","volume":"49","author":"Bardelas","year":"2012","journal-title":"J\u00a0Asthma"},{"key":"10.1016\/j.jaip.2019.03.008_bib62","doi-asserted-by":"crossref","first-page":"e55","DOI":"10.1542\/peds.110.5.e55","article-title":"Omalizumab improves asthma-related quality of life in children with allergic asthma","volume":"110","author":"Lemanske","year":"2002","journal-title":"Pediatrics"},{"key":"10.1016\/j.jaip.2019.03.008_bib63","doi-asserted-by":"crossref","first-page":"529","DOI":"10.3109\/02770903.2013.790419","article-title":"Effectiveness of omalizumab in severe allergic asthma: a retrospective UK real-world study","volume":"50","author":"Barnes","year":"2013","journal-title":"J\u00a0Asthma"},{"key":"10.1016\/j.jaip.2019.03.008_bib64","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.jaip.2018.04.043","article-title":"Omalizumab effectiveness by biomarker status in patients with asthma: evidence from PROSPERO, a prospective real-world study","volume":"7","author":"Casale","year":"2019","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2019.03.008_bib65","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.rmed.2017.01.008","article-title":"Long-term clinical outcomes of omalizumab therapy in severe allergic asthma: study of efficacy and safety","volume":"124","author":"Mansur","year":"2017","journal-title":"Respir Med"},{"key":"10.1016\/j.jaip.2019.03.008_bib66","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1016\/j.jaip.2017.02.002","article-title":"\u201cReal-life\u201d effectiveness studies of omalizumab in adult patients with severe allergic asthma: meta-analysis","volume":"5","author":"Alhossan","year":"2017","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2019.03.008_bib67","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1016\/j.rmed.2010.06.001","article-title":"Omalizumab reduces oral corticosteroid use in patients with severe allergic asthma: real-life data","volume":"104","author":"Molimard","year":"2010","journal-title":"Respir Med"},{"key":"10.1016\/j.jaip.2019.03.008_bib68","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/j.anai.2010.09.011","article-title":"Effectiveness of omalizumab in reducing corticosteroid burden in patients with moderate to severe persistent allergic asthma","volume":"105","author":"Karpel","year":"2010","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jaip.2019.03.008_bib69","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1378\/chest.125.4.1378","article-title":"Predicting response to omalizumab, an anti-IgE antibody, in patients with allergic asthma","volume":"125","author":"Bousquet","year":"2004","journal-title":"Chest"},{"key":"10.1016\/j.jaip.2019.03.008_bib70","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1164\/rccm.201208-1414OC","article-title":"Exploring the effects of omalizumab in allergic asthma: an analysis of biomarkers in the EXTRA study","volume":"187","author":"Hanania","year":"2013","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jaip.2019.03.008_bib71","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1111\/all.13302","article-title":"Response to omalizumab using patient enrichment criteria from trials of novel biologics in asthma","volume":"73","author":"Casale","year":"2018","journal-title":"Allergy"},{"key":"10.1016\/j.jaip.2019.03.008_bib72","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/j.rmed.2014.02.003","article-title":"Observational study in severe asthmatic patients after discontinuation of omalizumab for good asthma control","volume":"108","author":"Molimard","year":"2014","journal-title":"Respir Med"},{"key":"10.1016\/j.jaip.2019.03.008_bib73","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1111\/j.1398-9995.2009.02144.x","article-title":"After 6 years with Xolair: a 3-year withdrawal follow-up","volume":"65","author":"Nopp","year":"2010","journal-title":"Allergy"},{"key":"10.1016\/j.jaip.2019.03.008_bib74","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1136\/thoraxjnl-2017-210017","article-title":"Duration of the efficacy of omalizumab after treatment discontinuation in \u2018real life\u2019 severe asthma","volume":"73","author":"Vennera","year":"2018","journal-title":"Thorax"},{"key":"10.1016\/j.jaip.2019.03.008_bib75","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1111\/j.1365-2222.2009.03214.x","article-title":"Safety and tolerability of omalizumab","volume":"39","author":"Corren","year":"2009","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/j.jaip.2019.03.008_bib76","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1016\/j.jaci.2007.09.032","article-title":"American Academy of Allergy, Asthma & Immunology\/American College of Allergy, Asthma and Immunology Joint Task Force Report on omalizumab-associated anaphylaxis","volume":"120","author":"Cox","year":"2007","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2019.03.008_bib77","first-page":"231","article-title":"Eosinophil differentiation factor (interleukin-5)","volume":"49","author":"Sanderson","year":"1990","journal-title":"Immunol Ser"},{"key":"10.1016\/j.jaip.2019.03.008_bib78","doi-asserted-by":"crossref","first-page":"1776","DOI":"10.1126\/science.1100283","article-title":"A\u00a0critical role for eosinophils in allergic airways remodeling","volume":"305","author":"Humbles","year":"2004","journal-title":"Science"},{"key":"10.1016\/j.jaip.2019.03.008_bib79","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1111\/cea.12480","article-title":"The early history of the eosinophil","volume":"45","author":"Kay","year":"2015","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/j.jaip.2019.03.008_bib80","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1177\/1753465808092281","article-title":"Tissue remodeling and angiogenesis in asthma: the role of the eosinophil","volume":"2","author":"Nissim Ben Efraim","year":"2008","journal-title":"Ther Adv Respir Dis"},{"key":"10.1016\/j.jaip.2019.03.008_bib81","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1164\/ajrccm.161.1.9809100","article-title":"Changes in sputum eosinophils predict loss of asthma control","volume":"161","author":"Jatakanon","year":"2000","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jaip.2019.03.008_bib82","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1016\/S0140-6736(02)11679-5","article-title":"Asthma exacerbations and sputum eosinophil counts: a randomised controlled trial","volume":"360","author":"Green","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.jaip.2019.03.008_bib83","first-page":"321","article-title":"Technology evaluation: mepolizumab, GlaxoSmithKline","volume":"5","author":"Gnanakumaran","year":"2003","journal-title":"Curr Opin Mol Ther"},{"key":"10.1016\/j.jaip.2019.03.008_bib84","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1517\/14712598.2015.1090972","article-title":"Update on reslizumab for eosinophilic asthma","volume":"15","author":"Cardet","year":"2015","journal-title":"Expert Opin Biol Ther"},{"key":"10.1016\/j.jaip.2019.03.008_bib85","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/S2213-2600(16)30031-5","article-title":"Severe eosinophilic asthma treated with mepolizumab stratified by baseline eosinophil thresholds: a secondary analysis of the DREAM and MENSA studies","volume":"4","author":"Ortega","year":"2016","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.jaip.2019.03.008_bib86","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1056\/NEJMoa0808991","article-title":"Mepolizumab and exacerbations of refractory eosinophilic asthma","volume":"360","author":"Haldar","year":"2009","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jaip.2019.03.008_bib87","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1016\/j.jaci.2013.11.026","article-title":"Outcomes after cessation of mepolizumab therapy in severe eosinophilic asthma: a 12-month follow-up analysis","volume":"133","author":"Haldar","year":"2014","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2019.03.008_bib88","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/j.alit.2016.11.006","article-title":"Efficacy and safety of mepolizumab in Japanese patients with severe eosinophilic asthma","volume":"66","author":"Shimoda","year":"2017","journal-title":"Allergol Int"},{"key":"10.1016\/j.jaip.2019.03.008_bib89","doi-asserted-by":"crossref","first-page":"2058","DOI":"10.1016\/j.clinthera.2016.07.010","article-title":"Long-term efficacy and safety of mepolizumab in patients with severe eosinophilic asthma: a multi-center, open-label, phase IIIb study","volume":"38","author":"Lugogo","year":"2016","journal-title":"Clin Ther"},{"key":"10.1016\/j.jaip.2019.03.008_bib90","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1111\/all.12914","article-title":"Treatment response with mepolizumab in severe eosinophilic asthma patients with previous omalizumab treatment","volume":"71","author":"Magnan","year":"2016","journal-title":"Allergy"},{"key":"10.1016\/j.jaip.2019.03.008_bib91","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/S0140-6736(12)60988-X","article-title":"Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial","volume":"380","author":"Pavord","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.jaip.2019.03.008_bib92","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/S2213-2600(17)30125-X","article-title":"Efficacy of mepolizumab add-on therapy on health-related quality of life and markers of asthma control in severe eosinophilic asthma (MUSCA): a randomised, double-blind, placebo-controlled, parallel-group, multicentre, phase 3b trial","volume":"5","author":"Chupp","year":"2017","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.jaip.2019.03.008_bib93","first-page":"CD010834","article-title":"Anti-IL5 therapies for asthma","volume":"9","author":"Farne","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.jaip.2019.03.008_bib94","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1164\/rccm.201707-1323OC","article-title":"Weight-adjusted intravenous reslizumab in severe asthma with inadequate response to fixed-dose subcutaneous mepolizumab","volume":"197","author":"Mukherjee","year":"2018","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jaip.2019.03.008_bib95","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1164\/rccm.201611-2234OC","article-title":"Mepolizumab attenuates airway eosinophil numbers, but not their functional phenotype, in asthma","volume":"196","author":"Kelly","year":"2017","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jaip.2019.03.008_bib96","doi-asserted-by":"crossref","first-page":"AB409","DOI":"10.1016\/j.jaci.2017.12.965","article-title":"Efficacy and safety of mepolizumab in uncontrolled patients with severe eosinophilic asthma following a switch from omalizumab (OSMO study): exacerbation and safety outcomes","volume":"141","author":"Galkin","year":"2018","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2019.03.008_bib99","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1067\/mai.2001.116576","article-title":"Preclinical efficacy and safety of mepolizumab (SB-240563), a humanized monoclonal antibody to IL-5, in cynomolgus monkeys","volume":"108","author":"Hart","year":"2001","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2019.03.008_bib100","first-page":"779","article-title":"Effect of Sch 55700, a humanized monoclonal antibody to human interleukin-5, on eosinophilic responses and bronchial hyperreactivity","volume":"49","author":"Egan","year":"1999","journal-title":"Arzneimittelforschung"},{"key":"10.1016\/j.jaip.2019.03.008_bib101","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1164\/rccm.201810-1944CI","article-title":"Role of biologics in asthma","volume":"199","author":"McGregor","year":"2019","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jaip.2019.03.008_bib103","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1186\/s12931-018-0859-z","article-title":"The use of intravenous versus subcutaneous monoclonal antibodies in the treatment of severe asthma: a review","volume":"19","author":"Matucci","year":"2018","journal-title":"Respir Res"},{"key":"10.1016\/j.jaip.2019.03.008_bib104","first-page":"A7782","article-title":"Association between early improvements in lung function and asthma control with reslizumab and the annual rate of asthma exacerbations","volume":"193","author":"Bateman","year":"2016","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jaip.2019.03.008_bib105","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1016\/j.jaip.2017.08.024","article-title":"Long-term safety and efficacy of reslizumab in patients with eosinophilic asthma","volume":"5","author":"Murphy","year":"2017","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2019.03.008_bib106","doi-asserted-by":"crossref","first-page":"2448","DOI":"10.1056\/NEJMoa1703501","article-title":"Oral glucocorticoid-sparing effect of benralizumab in severe asthma","volume":"376","author":"Nair","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jaip.2019.03.008_bib107","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00936-2018","article-title":"Baseline patient factor impact on the clinical efficacy of benralizumab for severe asthma","volume":"52","author":"Bleecker","year":"2018","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jaip.2019.03.008_bib108","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1016\/j.jaci.2018.01.008","article-title":"Benralizumab attenuates airway eosinophilia in prednisone-dependent asthma","volume":"141","author":"Sehmi","year":"2018","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2019.03.008_bib109","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1080\/14740338.2016.1186641","article-title":"The safety of monoclonal antibodies in asthma","volume":"15","author":"Passalacqua","year":"2016","journal-title":"Expert Opin Drug Saf"},{"key":"10.1016\/j.jaip.2019.03.008_bib110","doi-asserted-by":"crossref","first-page":"799","DOI":"10.4049\/jimmunol.154.2.799","article-title":"IL-13 selectively induces vascular cell adhesion molecule-1 expression in human endothelial cells","volume":"154","author":"Bochner","year":"1995","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.jaip.2019.03.008_bib111","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1186\/rr52","article-title":"Eotaxin and the attraction of eosinophils to the asthmatic lung","volume":"2","author":"Conroy","year":"2001","journal-title":"Respir Res"},{"key":"10.1016\/j.jaip.2019.03.008_bib112","doi-asserted-by":"crossref","first-page":"S15","DOI":"10.1016\/j.jaip.2017.07.008","article-title":"New and anticipated therapies for severe asthma","volume":"5","author":"Peters","year":"2017","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2019.03.008_bib113","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1016\/S2213-2600(15)00197-6","article-title":"Efficacy and safety of tralokinumab in patients with severe uncontrolled asthma: a randomised, double-blind, placebo-controlled, phase 2b trial","volume":"3","author":"Brightling","year":"2015","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.jaip.2019.03.008_bib114","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/S2213-2600(16)30265-X","article-title":"Efficacy and safety of lebrikizumab in patients with uncontrolled asthma (LAVOLTA I and LAVOLTA II): replicate, phase 3, randomised, double-blind, placebo-controlled trials","volume":"4","author":"Hanania","year":"2016","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.jaip.2019.03.008_bib115","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1056\/NEJMoa1704064","article-title":"Tezepelumab in adults with uncontrolled asthma","volume":"377","author":"Corren","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jaip.2019.03.008_bib116","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1164\/rccm.201807-1205ED","article-title":"Biological treatments for eosinophilic asthma enter the airways","volume":"198","author":"Holguin","year":"2018","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jaip.2019.03.008_bib117","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1164\/rccm.201712-2382OC","article-title":"Efficacy of an inhaled IL-13 antibody fragment in a model of chronic asthma","volume":"198","author":"Lightwood","year":"2018","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jaip.2019.03.008_bib118","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1136\/thorax.58.4.322","article-title":"Risk factors associated with the presence of irreversible airflow limitation and reduced transfer coefficient in patients with asthma after 26 years of follow up","volume":"58","author":"Vonk","year":"2003","journal-title":"Thorax"},{"key":"10.1016\/j.jaip.2019.03.008_bib119","doi-asserted-by":"crossref","first-page":"603","DOI":"10.3109\/02770903.2014.895012","article-title":"Fixed airflow obstruction in asthma: a descriptive study of patient profiles and effect on treatment responses","volume":"51","author":"Tashkin","year":"2014","journal-title":"J\u00a0Asthma"},{"key":"10.1016\/j.jaip.2019.03.008_bib120","first-page":"55","article-title":"Omalizumab: the evidence for its place in the treatment of allergic asthma","volume":"3","author":"McNicholl","year":"2008","journal-title":"Core Evid"},{"key":"10.1016\/j.jaip.2019.03.008_bib121","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1378\/chest.119.4.1034","article-title":"Determinants of different dimensions of disease severity in asthma and COPD: pulmonary function and health-related quality of life","volume":"119","author":"Wijnhoven","year":"2001","journal-title":"Chest"},{"key":"10.1016\/j.jaip.2019.03.008_bib122","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1016\/j.rmed.2004.04.001","article-title":"The relationship between health-related quality of life, lung function and daily symptoms in patients with persistent asthma","volume":"98","author":"Carranza Rosenzweig","year":"2004","journal-title":"Respir Med"},{"key":"10.1016\/j.jaip.2019.03.008_bib123","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/j.jaci.2006.01.032","article-title":"Update on glucocorticoid action and resistance","volume":"117","author":"Ito","year":"2006","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2019.03.008_bib124","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1164\/rccm.201602-0419OC","article-title":"Inflammatory and comorbid features of patients with severe asthma and frequent exacerbations","volume":"195","author":"Denlinger","year":"2017","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jaip.2019.03.008_bib125","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1164\/rccm.201609-1819ED","article-title":"Exacerbation-prone asthma: a separate bioclinical phenotype?","volume":"195","author":"Loymans","year":"2017","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jaip.2019.03.008_bib126","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1111\/cea.12179","article-title":"Frequent exacerbators--a distinct phenotype of severe asthma","volume":"44","author":"Kupczyk","year":"2014","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/j.jaip.2019.03.008_bib127","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.jaci.2018.08.031","article-title":"Anti-IL-5 treatments in patients with severe asthma by blood eosinophil thresholds: indirect treatment comparison","volume":"143","author":"Busse","year":"2019","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2019.03.008_bib128","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.jaip.2018.08.036","article-title":"Reslizumab compared with benralizumab in patients with eosinophilic asthma: a systematic literature review and network meta-analysis","volume":"7","author":"Casale","year":"2019","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2019.03.008_bib129","first-page":"1","article-title":"A\u00a0cost-effectiveness analysis of reslizumab in the treatment of poorly controlled eosinophilic asthma","author":"Lam","year":"2018","journal-title":"J\u00a0Asthma"},{"key":"10.1016\/j.jaip.2019.03.008_bib130","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1007\/s40273-018-0658-x","article-title":"Cost-effectiveness of biological asthma treatments: a systematic review and recommendations for future economic evaluations","volume":"36","author":"McQueen","year":"2018","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.jaip.2019.03.008_bib131","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1111\/j.1398-9995.2006.01310.x","article-title":"Cost-effectiveness of omalizumab in patients with severe persistent allergic asthma","volume":"62","author":"Brown","year":"2007","journal-title":"Allergy"},{"key":"10.1016\/j.jaip.2019.03.008_bib132","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.jaci.2004.05.049","article-title":"Cost-effectiveness analysis of omalizumab in adults and adolescents with moderate-to-severe allergic asthma","volume":"114","author":"Oba","year":"2004","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2019.03.008_bib133","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1111\/j.1398-9995.2008.01723.x","article-title":"An evaluation of the cost-effectiveness of omalizumab for the treatment of severe allergic asthma","volume":"63","author":"Sullivan","year":"2008","journal-title":"Allergy"},{"key":"10.1016\/j.jaip.2019.03.008_bib134","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.anai.2016.10.028","article-title":"Assessing the value of mepolizumab for severe eosinophilic asthma: a cost-effectiveness analysis","volume":"118","author":"Whittington","year":"2017","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jaip.2019.03.008_bib135","series-title":"Biologic therapies for treatment of asthma associated with type 2 inflammation: effectiveness, value, and value-based price benchmarks","author":"Tice","year":"2018"}],"container-title":["The Journal of Allergy and Clinical Immunology: In Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213219819302715?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213219819302715?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T05:20:31Z","timestamp":1761974431000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213219819302715"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5]]},"references-count":131,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2019,5]]}},"alternative-id":["S2213219819302715"],"URL":"https:\/\/doi.org\/10.1016\/j.jaip.2019.03.008","relation":{},"ISSN":["2213-2198"],"issn-type":[{"value":"2213-2198","type":"print"}],"subject":[],"published":{"date-parts":[[2019,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Biologics for Severe Asthma: Treatment-Specific Effects Are Important in Choosing a Specific Agent","name":"articletitle","label":"Article Title"},{"value":"The Journal of Allergy and Clinical Immunology: In Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaip.2019.03.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 American Academy of Allergy, Asthma & Immunology","name":"copyright","label":"Copyright"}]}}